ORPH
Orphazyme A/S
ORPH
ORPH
Delisted
ORPH was delisted on the 30th of March, 2022.
About: Orphazyme AS is a late-stage biopharmaceutical company harnessing the amplification of Heat Shock Proteins. It is engaged in the development and commercialization of novel therapeutics for the treatment of neurodegenerative rare diseases. The company's lead candidate, Arimoclomol, is in development for four severe orphan diseases: Niemann-Pick disease Type C (NPC), Gaucher disease, Amyotrophic Lateral Sclerosis (ALS), and Inclusion Body Myositis (IBM).
Employees: 141
Charts implemented using
Lightweight Charts™